depended on FEV, (% predicted) more or less than 75%. Chrispin-Norman scores were calculated on all patients, whereby a lateral chest radiograph and the four quadrants of the lung fields on a posterior/anterior film were scored with regard to chest configuration and lung markings; a high score indicated a poor chest radiograph (maximum 38 points).9
It has long been the impression of clinicians that cystic fibrosis (CF), the most common serious autosomal recessive genetic disorder in Caucasian populations, is heterogeneous, with variable system involvement and disease severity. ' Since the identification of the most common CF mutation, AF508,24 and an increasing number of other mutations, comprehensive studies on phenotype/genotype comparisons have been published."
Johansen et a16 carried out a cross sectional study of Danish CF patients and found that AF508 homozygous positive patients had poorer lung function and an increased incidence of chronic infection with Pseudomonas aeruginosa in comparison with heterozygous patients. They also found a significant correlation and decline in FEV, and FVC with age in the homozygous but not in the heterozygous patients.
Patients and methods A cross sectional study was carried out on 127 CF patients living mainly in South Wales, age range 1 to 31 years. In order to exclude possible complicating factors associated with the presence of more than one affected subject in a family, patients who had sibs with CF (whether alive or dead) were excluded from the group analyses. However, two sets of sibs heterozygous for the Rl 17H mutation were examined separately. The age at diagnosis of CF (determined by clinical features and a positive sweat test) was noted.
Clinical classification of lung disease as 'mild' or 'moderate to severe' was carried out when patients were in a stable clinical state and depended on FEV, (% predicted) more or less than 75%. Chrispin-Norman scores were calculated on all patients, whereby a lateral chest radiograph and the four quadrants of the lung fields on a posterior/anterior film were scored with regard to chest configuration and lung markings; a high score indicated a poor chest radiograph (maximum 38 points). 9 Colonisation with Pseudomonas species was noted; patients were scored as positive if the organism was isolated even once, even though the infection was apparently not persistent. All parameters were assessed during the year before the analyses. Data were sought for nine different mutations:  AF508, AI507, 1717-IG>A, G551D, R553X,  G542X, R560T, R117H , and 621 + IG> T. The AF508 deletion was identified by amplification of genomic DNA by polymerase chain reaction (PCR), followed by direct measurement of the size of the PCR product on a denaturing polyacrylamide gel. Multiplex PCR was used in some patients to screen simultaneously for five mutations (J P Cheadle, personal communication substitutions since, has provided the opportunity to study the relationship between CF phenotype and allelic heterogeneity at the CF locus. This cross sectional study involved 127 CF patients living in various parts of Wales, more than 50% of whom were from south Wales. Respiratory funrtion tests showed a significant decline of lung function with age for both AF508 (+ +) and (+ -) patients. Although the shapes of these lung function curves were quite similar to those of Johansen et al,6 these authors did not find a significant decline in lung function tests among their heterozygous patients. From our data, we disagree with their conclusion that the homozygous patients necessarily have poorer lung function. In our study, the median lines for decline of FEV1
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and FVC (% predicted) correlated significantly with age, for both homozygous and heterozygous AF508 patients. In both studies (that of Johansen et a16 and our study) an examination of FEV,% predicted for the AF508 heterozygous patients shows two populations at least: one population where lung function deteriorates severely with age and finally incapacitates the patients at around 16 to 20 years of age, and another population comprising the fitter, more mildly affected patients, contributing to the upturn in the curve. In the first population of the AF508 heterozygous patients in our study, a number of patients fell well below the FEV,% curve of median fit; among these were two patients heterozygous for 621 + IG> T, one patient heterozygous for G551D, and four who screened negative for the nine mutations analysed but who may carry one or more 'minor' mutations causing severe chest disease. The second population contributing to the upturn in the curve included five patients, of whom two carried G551D and three were screened negative for the nine mutations analysed.
A Graphs were not drawn for the AF508 (--) patients because numbers were small; however, it was noted that five of these nine patients for whom respiratory function data were available showed a severe decline of lung function at more than 15 years of age. Among those five patients were one who carried (G551D/-) genotype with FEV, of 77% and two who carried (621 + IG> T/-) genotype with FEV, of 30% and 40% and two who screened negative for the nine mutations analysed, with FEVI of 28% and 92%.
As expected, there was a significant decline in Chrispin Norman scores with age among AF508 (+ +) and (+ -) patients. Although the number of AF508 (--) patients was small, the decline in these scores was more pronounced at 15 years of age and older. It could be argued that the AF508 (--) patients have the genetic advantage earlier in life with well maintained respiratory function and a lesser need for aggressive treatment regimens and hospital admissions. However, they may lose this advantage as they grow older and as environmental factors which are known to influence chest disease have more cumulative effect, so causing the severe deterioration in pulmonary function at an older age. A 17 year old patient with AF508 (--), whose FEV,% and FVC% were 28% and 60% of predicted, died during the study.
In contrast to other studies, we did not find a significant correlation between age at diagnosis and AF508 status,56 nor did we find an association between AF508 status and colonisation with Pseudomonas species, which again is different from other surveys.67 As expected, patients with moderate to severe chest disease had a significantly higher incidence of Pseudomonas species infection, whether they carried AF508 (+ +) or (+ -) genotypes, compared with those with mild chest disease.
This study has shown that patients heterozygous for the 621 + IG> T mutation, which has a high frequency among Welsh patients (Cheadle et al, personal communication), may have a predisposition to severe chest disease. Although total numbers were small, three out of five patients with 621 + IG > T/AF508 genotype, aged 15 to 20 years, had an FEV, <50% predicted, compared with two out of eight patients who were AF508 homozygous positive in the same age group. Among the total of 77 patients who had pulmonary function tests, 15 patients had an FEV,% < 50% of predicted, of whom five were heterozygous for 621 + IG > T mutation. This apparent predisposition has not been reported before.
There is considerable evidence that CF patients carrying the Rl 17H mutation, even in single copy, have milder disease.101' It may be relevant that one of our sib pairs with this mutation was diagnosed late (at 6 and 15 years) and that the older of the younger pair was recognised at 2 years, when his younger sister was positive on neonatal screening. Owing to the late diagnosis of the older pair (with absence of specific treatment for CF before this) and the youth of the younger pair, we are unable to advance the case that these four patients who are heterozygous for the RI 17H mutation are definitely 'mild', but they would seem to be so.
A longitudinal study over several years to follow up patients of different genotypes should be more informative than the present cross sectional one.
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